Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Neurocrine Biosciences (NBIX) Accumulated Depreciation & Amortization (2016 - 2025)

Neurocrine Biosciences filings provide 15 years of Accumulated Depreciation & Amortization readings, the most recent being $118.3 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 11.08% to $118.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $118.3 million, a 11.08% increase, with the full-year FY2025 number at $118.3 million, up 11.08% from a year prior.
  • Accumulated Depreciation & Amortization hit $118.3 million in Q4 2025 for Neurocrine Biosciences, up from $106.5 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $118.3 million in Q4 2025 to a low of $51.9 million in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $83.0 million (2023), compared with a mean of $85.2 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: rose 28.31% in 2024 and later rose 11.08% in 2025.
  • Neurocrine Biosciences' Accumulated Depreciation & Amortization stood at $51.9 million in 2021, then rose by 27.75% to $66.3 million in 2022, then rose by 25.19% to $83.0 million in 2023, then grew by 28.31% to $106.5 million in 2024, then rose by 11.08% to $118.3 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $118.3 million (Q4 2025), $106.5 million (Q4 2024), and $83.0 million (Q4 2023) per Business Quant data.